NEW YORK (CBSNewYork/AP) — Republican U.S. Rep. Christopher Collins of New York was arrested Wednesday on charges he fed inside information that he gleaned from sitting on the board of a biotechnology company to his son, helping others dodge hundreds of thousands of dollars in losses when bad news came out.

The charges were announced against Collins, a staunch supporter of President Donald Trump who is up for re-election in November.

READ MORE: Gabby Petito Foundation Holds Fundraiser On Long Island

An indictment unsealed in federal court in Manhattan charges Collins, the congressman’s son and the father of the son’s fiance with conspiracy, wire fraud and other counts.

More From CBS News

Prosecutors say the charges relate to a scheme to gain insider information about Innate Immunotherapeutics Limited, a biotechnology company headquartered in Sydney, Australia, with offices in Auckland, New Zealand.

According to the indictment, the defendants tried to get early word on the results of trials of a drug the company developed to treat multiple sclerosis.

More: Read the indictment against Rep. Chris Collins

The 68-year-old Collins, a conservative who was first elected in 2014 to represent parts of western New York between Buffalo and Rochester, has denied any wrongdoing. When the House Ethics Committee began investigating the stock trades a year ago, his spokeswoman called it a “partisan witch hunt.”

“We will answer the charges filed against Congressman Collins in court and will mount a vigorous defense to clear his good name,” his attorneys, Jonathan Barr and Jonathan New, said in a statement Wednesday. “It is notable that even the government does not allege that Congressman Collins traded a single share of Innate Therapeutics stock. We are confident he will be completely vindicated and exonerated.”

All three defendants were in federal custody Wednesday and were expected to make their initial court appearance in the afternoon. Prosecutors also planned to hold a news conference.

Collins has a track record of publicly backing Trump, including being one of the first sitting members of Congress to endorse his candidacy. Most recently, Collins called for an end to Special Counsel Robert Mueller’s probe into campaign collusion and blaming the Obama Administration for failing to push back on Russia.

“I share President Trump’s continued frustration as the left continues to try to nullify the 2016 Presidential election with claims of Russian interference,” he said.

READ MORE: NYPD: Delivery Worker Stabbed To Death, E-Bike Stolen Near Sara D. Roosevelt Park

Collins ran unopposed in the Republican primary and holds what’s largely considered a safe Republican seat in a state that went to Democratic nominee Hillary Clinton in 2016. He’s being challenged by Democrat Nate McMurray, a Grand Island, New York, town supervisor.

Speaker Paul Ryan said Wednesday that he was removing Collins from the House Energy and Commerce Committee and prodded his chamber’s ethics panel to pursue “a prompt and thorough investigation” of the lawmaker.

Ryan said he was taking the actions even though the courts will have to decide whether the western New York lawmaker is guilty of the allegations.

“Insider trading is a clear violation of the public trust,” said Ryan, R-Wis.

The House Ethics Committee acknowledged last August that it had received a report from the independent Office of Congressional Ethics, which urged an investigation of Collins’ actions. The Ethics Committee formally acknowledged its investigation in October.

The advocacy group Public Citizen had claimed Collins was potentially involved in insider trading of shares of Innate Immunotherapeutics, which was experimenting with a drug for treating multiple sclerosis.

A seat on the Energy and Commerce panel is highly coveted because of its wide jurisdiction. It’s the only major committee on which Collins serves.

The congressman was a member of Innate’s board of directors and held nearly 17 percent of the stock. When the drug trials failed, the public announcement caused the stock price of Innate to plunge 92 percent.

Prosecutors allege that Collins passed along secrets to his son, Cameron, in June 2017. They say the son traded on the inside information and passed it to a third defendant, Stephen Zarsky. They say Zarsky traded on it and tipped off at least three others.

Prosecutors say the three avoided over $768,000 in losses by trading ahead of the public announcement of the failed drug trials.

The advocacy group Public Citizen filed a request for an investigation of Collins’ stock dealings with the Office of Congressional Ethics and the Securities and Exchange Commission in January of 2017.

MORE NEWS: Sharee Jones Charged With Arson, Hate Crime After Fire At Brooklyn Yeshiva

(© Copyright 2018 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)